Last update Nov. 15, 2015

Molgramostim

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

INon-glycosylated stimulating factor of granulocyte colonies (G-CSF) which is obtained by recombinant technology. It is practically identical to the naturally occurring product that is found in the breast milk.
It is indicated for the treatment of cancer-related neutropenia, and autologous bone marrow transplantation.

At last update no published data on excretion in breast milk were found.

A high molecular weight makes unlikely its excretion into breastmilk in a significant amount.
Its low oral bioavailability hampers absorption into infant plasma from the breast milk ingested, as for their proteic nature it is degraded in the gastrointestinal tract, not being absorbed.

Other substances similar in composition and action as Filgrastim and Lenograstim are excreted into breast milk in trace amounts and have been used to treat sepsis and necrotizing enterocolitis in newborn and premature without harmful effects in the infants.

Until more data about this drug regarding breastfeeding is obtained, alternatives that are known to be safer should be preferable, especially during the neonatal period and/or in case of prematurity.

Alternatives

  • Filgrastim ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Lenograstim ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Molgramostim in other languages or writings:

Group

Molgramostim belongs to this group or family:

Tradenames

Main tradenames from several countries containing Molgramostim in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 14478 daltons
Tmax 3 - 46 hours
1 - 3 hours

References

  1. Pessach I, Shimoni A, Nagler A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know? Hum Reprod Update. 2013 Abstract Full text (link to original source) Full text (in our servers)
  2. Kaida K, Ikegame K, Fujioka T, Taniguchi Y, Inoue T, Hasei H, Tamaki H, Yoshihara S, Kawase I, Ogawa H. Kinetics of granulocyte colony-stimulating factor in the human milk of a nursing donor receiving treatment for mobilization of the peripheral blood stem cells. Acta Haematol. 2007 Abstract Full text (link to original source) Full text (in our servers)
  3. Canpolat FE, Yurdakök M, Korkmaz A, Yiğit S, Tekinalp G. Enteral granulocyte colony-stimulating factor for the treatment of mild (stage I) necrotizing enterocolitis: a placebo-controlled pilot study. J Pediatr Surg. 2006 Abstract
  4. Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A, Messina G, Pontari A, Pucci G, Furlò G, Bresolin G, Iacopino P, Morabito F. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher. 2005 Abstract
  5. Shibata H, Yamane T, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C, Terada Y, Koh G, Hino M. Excretion of granulocyte colony-stimulating factor into human breast milk. Acta Haematol. 2003 Abstract Full text (link to original source) Full text (in our servers)
  6. Calhoun DA, Maheshwari A, Christensen RD. Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. Pediatrics. 2003 Abstract
  7. Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev. 2003 Abstract
  8. Bedford Russell AR, Emmerson AJ, Wilkinson N, Chant T, Sweet DG, Halliday HL, Holland B, Davies EG. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed. 2001 Abstract Full text (link to original source) Full text (in our servers)
  9. EMA. Molgramostin. Ficha técnica. 2000 Full text (in our servers)
  10. EMA. Molgramostin. Drug Summary 2000 Full text (in our servers)
  11. Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood. 1994 Abstract Full text (link to original source) Full text (in our servers)

Total visits

2,666

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM